EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Margetuximab for HER2-Positive Breast Cancer.

Citation metadata

Date: Sept. 2021
From: Oncology(Vol. 35, Issue 9)
Publisher: Intellisphere, LLC
Document Type: Brief article
Length: 349 words
Lexile Measure: 1120L

Document controls

Main content

Source Citation

Source Citation   

Gale Document Number: GALE|A679525839